DE69433820D1 - Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten - Google Patents

Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten

Info

Publication number
DE69433820D1
DE69433820D1 DE69433820T DE69433820T DE69433820D1 DE 69433820 D1 DE69433820 D1 DE 69433820D1 DE 69433820 T DE69433820 T DE 69433820T DE 69433820 T DE69433820 T DE 69433820T DE 69433820 D1 DE69433820 D1 DE 69433820D1
Authority
DE
Germany
Prior art keywords
monoclonal antibodies
ligands
preventing
production
medicinal product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69433820T
Other languages
English (en)
Other versions
DE69433820T2 (de
Inventor
J Armitage
C Fanslow
L Longo
J Murphy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
National Institutes of Health NIH
Original Assignee
Immunex Corp
National Institutes of Health NIH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22628670&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69433820(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp, National Institutes of Health NIH filed Critical Immunex Corp
Application granted granted Critical
Publication of DE69433820D1 publication Critical patent/DE69433820D1/de
Publication of DE69433820T2 publication Critical patent/DE69433820T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
DE69433820T 1993-12-23 1994-12-21 Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten Revoked DE69433820T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US172664 1988-03-24
US17266493A 1993-12-23 1993-12-23
PCT/US1994/014767 WO1995017202A1 (en) 1993-12-23 1994-12-21 Method of preventing or treating disease characterized by neoplastic cells expressing cd40

Publications (2)

Publication Number Publication Date
DE69433820D1 true DE69433820D1 (de) 2004-07-01
DE69433820T2 DE69433820T2 (de) 2005-06-23

Family

ID=22628670

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69433820T Revoked DE69433820T2 (de) 1993-12-23 1994-12-21 Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten

Country Status (13)

Country Link
US (1) US5674492A (de)
EP (1) EP0751781B1 (de)
JP (1) JPH09507074A (de)
AT (1) ATE267607T1 (de)
AU (1) AU680102B2 (de)
CA (1) CA2179196A1 (de)
DE (1) DE69433820T2 (de)
DK (1) DK0751781T3 (de)
ES (1) ES2222463T3 (de)
NO (1) NO320354B1 (de)
NZ (1) NZ278740A (de)
PT (1) PT751781E (de)
WO (1) WO1995017202A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US6132978A (en) * 1995-12-19 2000-10-17 National Jewish Medical And Research Center Method to regulate CD40 signaling
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
NZ337073A (en) * 1997-01-10 2001-01-26 Biogen Inc use of an anti CD40L compound to treat a patient with an autoimmune disease or chronic immune system disorder
EA200000087A1 (ru) * 1997-07-01 2000-08-28 Атеродженикс, Инк. Повышение эффективности терапии гиперпролиферативных состояний с помощью антиоксиданта
JP2001526241A (ja) * 1997-12-19 2001-12-18 イミュネックス・コーポレーション Ｈｉｖ感染に対する感受性を低下させるための方法
US7338767B1 (en) 1998-01-14 2008-03-04 Dana-Farber Cancer Institute, Inc. Use of microphthalmia for diagnosis, prognosis and/or treatment of melanoma
WO1999036783A1 (en) * 1998-01-14 1999-07-22 Dana-Farber Cancer Institute, Inc. Use of microphthalmia for diagnosis of melanoma
US5965712A (en) * 1998-06-19 1999-10-12 Virginia Commonwealth University LZ-CD23 chimera for inhibition of IgE-mediated allergic disease
CA2344655A1 (en) * 1998-09-29 2000-04-06 The Uab Research Foundation Immunomodulation by genetic modification of dendritic cells and b-cells
AU2215700A (en) * 1998-12-29 2000-07-31 University Of Vermont And State Agricultural College, The Use of cd40 engagement to alter t cell receptor usage
EP1185627A2 (de) * 1999-06-01 2002-03-13 Cornell Research Foundation, Inc. Aktivierung von dendritischen zellen zur verstärkung der immunität
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US6482411B1 (en) 1999-08-27 2002-11-19 Board Of Regents, The University Of Texas System Methods of reducing bone loss with CD40 ligand
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
WO2001056603A1 (en) 2000-02-01 2001-08-09 Tanox, Inc. Cd40-binding apc-activating molecules
ES2528794T3 (es) 2000-04-11 2015-02-12 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
ES2254408T4 (es) * 2000-04-25 2007-10-01 Immunex Corporation Procedimiento de tratamiento de tumores usando terapia fotodinamica.
CN1437478A (zh) * 2000-04-25 2003-08-20 Idec药物公司 瑞图希单抗的鞘内施用,用于中枢神经系统淋巴瘤的治疗
JP4271440B2 (ja) * 2000-10-02 2009-06-03 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ヒト抗ｃｄ４０抗体
US20030202963A1 (en) * 2000-10-12 2003-10-30 Cornell Research Foundation, Inc. Method of treating cancer
GB0025132D0 (en) * 2000-10-13 2000-11-29 Medical Res Council Method
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
WO2002060485A2 (en) 2001-01-31 2002-08-08 Idec Pharmaceuticals Corporation Use of immunoregulatory antibodies in the treatment of neoplastic disorders
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
DE60239931D1 (de) * 2001-04-02 2011-06-16 Genentech Inc Kombinationstherapie
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
PL1684805T3 (pl) 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostics Inc Sposoby leczenia szpiczaka mnogiego z zastosowaniem antagonistycznych monoklonalnych przeciwciał przeciwko CD40
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
PL1680141T3 (pl) * 2003-11-04 2011-04-29 Novartis Vaccines & Diagnostics Inc Sposoby leczenia guzów litych wykazujących ekspresję antygenu powierzchniowego CD40
JP4810431B2 (ja) 2003-11-04 2011-11-09 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｂ細胞に関連する癌に対する治療方法
ATE447412T1 (de) 2003-11-04 2009-11-15 Novartis Vaccines & Diagnostic Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren
EP2243491A1 (de) 2003-11-04 2010-10-27 Novartis Vaccines and Diagnostics, Inc. Verwendung von antagonistischen anti-CD40-Antikörpern zur Behandlung von chronischer lymphatischer Leukämie
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
DK1889065T3 (da) 2005-05-18 2013-09-02 Xoma Technology Ltd Metoder til diagnostisering og behandling af sygdomme med en autoimmun- og/eller inflammationskomponent
US8303955B2 (en) * 2005-05-26 2012-11-06 Seattle Genetics, Inc. Humanized anti-CD40 antibodies and their methods of use
ES2400660T3 (es) 2005-11-01 2013-04-11 Novartis Ag Usos de anticuerpos anti-CD40
MEP39508A (en) 2006-04-21 2011-02-10 Novartis Ag Antagonist anti-cd40 antibody pharmaceutical compositions
MX2008013993A (es) * 2006-05-03 2009-05-11 Univ Colorado Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular.
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
JP5730576B2 (ja) 2007-11-07 2015-06-10 ジェネンテック， インコーポレイテッド 抗ｃｄ４０抗体による治療に対するｂ細胞リンパ腫の応答性を評価するための方法及び組成物
CA2758523C (en) 2009-04-18 2019-03-12 Genentech, Inc. Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
AU2012245309C1 (en) 2011-04-21 2016-07-21 Bristol-Myers Squibb Company Antibody polypeptides that antagonize CD40
EP3508500A1 (de) 2011-04-29 2019-07-10 Apexigen, Inc. Anti-cd40-antikörper und verfahren zur verwendung
CN104918957B (zh) * 2012-10-30 2018-11-16 埃派斯进有限公司 抗-cd40抗体及其使用方法
EP3113796A1 (de) 2014-03-07 2017-01-11 Bristol-Myers Squibb Company Verfahren zur verwendung von antikörperpolypeptiden mit cd40-antagonisierung zur behandlung von entzündlichen darmerkrankungen
HUE048284T2 (hu) 2015-05-29 2020-07-28 Abbvie Inc Anti-CD40 antitestek és alkalmazásuk
WO2017156349A1 (en) 2016-03-10 2017-09-14 Cold Genesys, Inc. Methods of treating solid or lymphatic tumors by combination therapy
MA44723A (fr) 2016-04-18 2019-02-27 Celldex Therapeutics Inc Anticorps agonistes se liant au cd40 humain et leurs utilisations
EP3450556B1 (de) * 2016-04-27 2022-03-23 Osaka University Peptid zur hemmung der kolonisation durch pathogene bakterien und kolonisationsinhibitor damit
TWI784957B (zh) 2016-06-20 2022-12-01 英商克馬伯有限公司 免疫細胞介素
WO2022165171A1 (en) 2021-01-28 2022-08-04 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5247069A (en) * 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
US5182368A (en) * 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation
SE8701004D0 (sv) * 1987-03-11 1987-03-11 Astra Ab Method for therapy of leukemias and certain other malignancies
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE239790T1 (de) * 1991-10-25 2003-05-15 Immunex Corp Antikörper gegen cd40-l
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
GB9425060D0 (en) * 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment

Also Published As

Publication number Publication date
PT751781E (pt) 2004-09-30
ES2222463T3 (es) 2005-02-01
NO320354B1 (no) 2005-11-28
EP0751781B1 (de) 2004-05-26
JPH09507074A (ja) 1997-07-15
EP0751781A4 (de) 1999-09-22
AU680102B2 (en) 1997-07-17
EP0751781A1 (de) 1997-01-08
WO1995017202A1 (en) 1995-06-29
US5674492A (en) 1997-10-07
DK0751781T3 (da) 2004-08-09
AU1516895A (en) 1995-07-10
DE69433820T2 (de) 2005-06-23
NZ278740A (en) 1998-05-27
NO962526D0 (no) 1996-06-14
NO962526L (no) 1996-08-23
CA2179196A1 (en) 1995-06-29
ATE267607T1 (de) 2004-06-15

Similar Documents

Publication Publication Date Title
DE69433820D1 (de) Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
ATE324884T1 (de) Verwendung von gamma-linolensäure oder dihomogammalinolensäure zur herstellung eines medikaments zur behandlung von huntington's chorea
ATE156018T1 (de) Verwendung von igf1 oder igf2 zur herstellung eines medikaments für die behandlung von amyotrophischen lateralsklerose
DE69533040D1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
DE69433013D1 (de) Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
ATE180408T1 (de) Herstellung eines arzneimittels zur behandlung von augenentzündung durch blockierung von zelladhäsionsmolekulen
SE8902638L (sv) Stabiliserade protein- eller peptidkonjugat
ATE254926T1 (de) Verwendung eines consensus-interferons zur reduzierung der nebeneffekte in der interferon behandlung von viralen hepatiten.
NO20092874L (no) Forhindring og behandling av amyloidogen sykdom
DK1014996T3 (da) Præparater indeholdende saccharid til behandling af Alzheimers sygdom og andre amyloidoser
ATE101648T1 (de) Expression eines tumorspezifischen antigens eines rekombinanten virusvektors sowie dessen anwendung zur versorgenden oder heilenden behandlung des entsprechenden tumors.
DE69229050D1 (de) Verwendung von Papillomavirusprotein L2 zur therapeutischen Behandlung von durch Papillomavirus hervorgerufenen Tumoren oder oder anderen krankhaften Veränderungen
DE69425246D1 (de) Monoklonale antikoerper gegen lfa-1 zur herstellung eines arzneimittels zur vorbeugung der transplantatabstossung von organen
ATE98869T1 (de) Pharmazeutisches mittel fuer behandlung von menschlichem krebs und verfahren zu seiner herstellung.
GEP20002257B (en) Method for Reducing Fibrin Accumulation Speed, Prophylactics of Thrombus Complications and Treatment of Blood Vessels Diseases, Medicinal Composition and Medicinal Species
IL99940A0 (en) Beta-galactoside binding proteins,methods for the production thereof,and pharmaceutical compositions containing the same
ATE194076T1 (de) Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen
ATE239492T1 (de) Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen
ATE264112T1 (de) Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus
DE69221605D1 (de) Nicht-zellzahlverringernde cd4-spezifische monoklonale antikörper zur behandlung von insulinabhängigem diabetes mellitus (iddm)
DE69428797T2 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
DE60037402D1 (de) Behandlung von autoimmunkrankheiten mit einem extrakt von amerikanischem ginseng
NZ329403A (en) Treatment of B-cell lymphomas using a CD40 binding protein that inhibits the binding of CD40 to CD40L
DE69732851D1 (de) Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren
RU97112310A (ru) Способ лечения язвенной болезни

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation